Edwards, Medtronic heart valve systems prove worth in low-risk patients: studies

By Tamara Mathias (Reuters) - Non-invasive heart valve replacement systems from Medtronic Plc and rival Edwards Lifesciences Corp proved as good or better than open heart surgery in younger, more active patients for whom the surgical option was deemed low risk, according to trial results that had been scheduled to be presented on Sunday. Both companies already have approvals for their TAVR (transcatheter aortic valve replacement) systems for use in patients too frail to endure surgery and those deemed at intermediate risk. Approvals in low-risk patients would open up a large new population for the devices seen as vital growth drivers for the companies.

The post Edwards, Medtronic heart valve systems prove worth in low-risk patients: studies appeared first on Firstpost.